Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mochida: Epadel, Atelec Drive Growth in Sales, Profits
May 29, 2006
- Basic Policies for Animal Studies Approved: Korosho
May 29, 2006
- Pfizer Japan's MRs Remain
May 22, 2006
- BUSINESS NEWS IN BRIEF
May 22, 2006
- Plan of Action for Industry Vision Reviewed
May 22, 2006
- Japan Pediatric Society's Scientific Meeting
May 22, 2006
- Mr Nogimori Wants to Make
May 22, 2006
- REGULATORY NEWS IN BRIEF
May 22, 2006
- SURVEY 3 articles
May 22, 2006
- NEW PRODUCTS
May 22, 2006
- Tanabe Seiyaku Announces
May 22, 2006
- Eisai Starts PI Trial for
May 22, 2006
- Daiichi Sankyo: Olmesartan
May 22, 2006
- CPHI JAPAN 2006
May 22, 2006
- DSP to See Combined Sales of
May 22, 2006
- R&D NEWS IN BRIEF
May 22, 2006
- MPC Predicts 3rd-Straight Year of Record Profits
May 22, 2006
- Projections of Med. Expenditure
May 22, 2006
- Teijin: Medical/Pharmaceutical
May 22, 2006
- Novartis to Launch
May 22, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…